Diagonal Bio announces strategic pilot study with Löberöds Hästklinik
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) is pleased to announce a significant new collaboration with Löberöds Hästklinik, led by renowned sporthorse veterinarian Lisa Lidbeck. The agreement, set to last an initial term of three months, will involve a pilot testing program focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of respiratory viral infections in sporthorses.
Lisa Lidbeck, an FEI (Fédération Equestre International-Internationella Ridsportförbundet) Veterinarian, and former Team Veterinarian for the Swedish National Eventing Team, brings a wealth of experience and an extensive international network to this collaboration. Her expertise in managing health care for high-performance sporthorses is expected to be instrumental in advancing Diagonal Bio’s platform technology, LAMPlify®, and veterinary diagnostic capabilities. The collaboration aims to leverage Lisa Lidbeck's deep understanding of equine health challenges, particularly in high-stakes competitive environments.
The agreement is set for an initial three-month pilot study and represents a strategic opportunity to refine and expand the Company's diagnostic solutions within the veterinary field. This initiative is aimed at enhancing health outcomes for sporthorses and ensuring more secure equestrian events globally.
Only in Europe, there are a vast number of horse events yearly. In UK and France, there were more than 17 000 competitions in 2023.
"At major equestrian competitions, it is crucial that we quickly can isolate horses with suspected viral infections. Horses that compete internationally are extremely valuable, and having to wait for the compulsory PCR analysis result for several days can be devastating. This collaboration with Diagonal Bio will enable us to implement fast and accurate diagnostics, safeguarding both the horses and the events they participate in” - Lisa Lidbeck, sporthorse veterinarian at Löberöd Hästklinik.
“Through our collaboration with Lisa Lidbeck and Löberöd Hästklinik, Diagonal Bio is taking a significant step towards transforming veterinary diagnostics. Our goal is not just to provide rapid testing solutions, but to ensure the health and safety of competition horses at a global level. This collaboration underlines our commitment to advancing healthcare by integrating cutting-edge technology with veterinary expertise” - Karin Wehlin, CEO of Diagonal Bio AB (publ).
For more information about the Company, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: kw@diagonalbio.com
www.diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on May 15, 2024, at 12:30 CET.
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.